

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



CC E

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|------------------|--|
| <p>(51) International Patent Classification⁵ : A61K 31/70</p> | <p>A1</p> | <p>(11) International Publication Number: WO 94/14456 (43) International Publication Date: 7 July 1994 (07.07.94)</p> |
| <p>(21) International Application Number: PCT/CA93/00563 (22) International Filing Date: 22 December 1993 (22.12.93) (30) Priority Data: 92269273 24 December 1992 (24.12.92) GB (71) Applicant (for all designated States except US): BIOCHEM PHARMA INC. (CA/CA); 275 Armand-Frappier Boulevard, Laval, Quebec H7V 4A7 (CA). (72) Inventors; and (73) Inventors/Applicants (for US only): MANSOUR, Tarek (CA/CA); 551 des Prairies Boulevard, Building 10, Laval, Quebec H7V 1B7 (CA). TSE, Alan, H., L. (HK/CA); 531 des Prairies Boulevard, Building 10, Laval, Quebec H7V 1B7 (CA). (74) Agents: BERESKIN & PARR; 40 King Street West, 40th floor, Toronto, Ontario M5H 3Y2 (CA).</p> | | <p>(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i></p> |
| <p>(54) Title: USE OF DIBOXY NUCLEOSIDE ANALOGUES IN THE TREATMENT OF VIRAL INFECTIONS (57) Abstract The present invention concerns the use and method of treatment of β-L-5-fluoro-2',3'-dideoxycytidine (β-L-5F-ddC), and β-L-2',3'-dideoxycytidine (β-L-ddC) and pharmaceutically acceptable derivatives thereof, for use in the treatment of viral infections, specifically HIV and hepatitis B infections. The present invention also includes the use and method of treatment of β-D-5-fluoro-2',3'-dideoxycytidine (β-D-5F-ddC) for use in the treatment of hepatitis B infections.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Cote d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LR | Sierra Leone | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| DJ | Djibouti | MH | Marshall Islands | US | United States of America |
| FI | Finland | ML | Mali | UZ | Uzbekistan |
| FR | France | MN | Mongolia | VN | Viet Nam |
| GA | Gabon | | | | |

Use of Dideoxy Nucleoside Analogues
in the Treatment of Viral Infections

The present invention relates to nucleoside analogues and their use in medicine. More specifically the invention is concerned with dideoxy nucleoside analogues, pharmaceutical formulations thereof and the use thereof in the treatment of viral infections.

10 The only compounds currently approved for the treatment of conditions caused by HIV are D-3'-azido-3'-deoxythymidine (AZT, zidovudine, BW 509U) and β -D-2',3'-dideoxyinosine (ddI, didanosine) which has been approved for use in patients who are intolerant to AZT. Also, β -D-2',3'-dideoxycytidine (ddC) has received approval only in combination with AZT. The above compounds derived from physiologically important nucleosides have significant side-effect liability and dose-limiting toxicity. Additionally, resistance to AZT, ddC and ddI has emerged

20 (K.J. Connolly and S.M. Hammer, Antimicrob. Agent. Chemother. 1992; 36, 245-254).

There is, in consequence, a continuing need to provide compounds which are effective against HIV but with a concomitant significantly better therapeutic index (i.e. more selective).

The compounds mentioned above are all used in the form of their natural enantiomers (D sugars). The

corresponding unnatural enantiomers of AZT (L-AZT) and ddI (β -L-ddI) have been found to be inactive against HIV (J. Wengel et al. J. Org. Chem, 1991; 56, 3591-3594; and M.M. Mansuri et al. BioMed. Chem. Lett. 1991; 1, 65-68) whereas the unnatural enantiomer of ddC (β -L-ddC) was reported to be inactive or weakly active against HIV (M. Okabe & al. J. Org. Chem. 1988; 54, 4780-4786 and M.M. Mansuri & al. Bio Med. Chem. Lett. 1991; 1, 65-68) with no mention of selectivity. Furthermore, there has been no report in the
10 literature about the activity of β -L-ddC against the Hepatitis B virus (HBV).

We have now found that, surprisingly, β -L-ddC, the unnatural (-)-enantiomer of ddC is active against HIV with unexpectedly high selectivity.

Furthermore, we have also found, unexpectedly, that β -L-ddC possesses excellent activity against Hepatitis B virus.

Moreover, the 5-fluoro analogue of ddC (5F-ddC) has
20 been described and tested in the form of its natural enantiomer (β -D-5F-ddC) and found to be active against HIV (Kim et al., J. Med. Chem. 1987: 30, 862-866). However, its activity against HBV has not been reported.

We have found that the natural enantiomer of 5F-ddC (β -D-5F-ddC) is active against against HBV.

In addition, there has been no reports of the activity of its corresponding unnatural enantiomer (β -L-5F-ddC) against HIV or HBV.

We have also found, unexpectedly, that the unnatural enantiomer of 5F-ddC (β -L-5F-ddC) possesses activity against HIV and HBV below its cytotoxic concentration.

SUMMARY OF THE INVENTION

There is thus provided, in a first aspect of the invention, the use of the (-)-enantiomer of ddC (β -L-ddC) and pharmaceutically acceptable derivatives thereof in the treatment of HIV infection.

There is also provided, in a second aspect of the invention, the use of β -L-ddC and pharmaceutically acceptable derivatives thereof in the treatment of HBV infections.

There is further provided, in a third aspect of the invention, the use of β -D-5F-ddC and pharmaceutically acceptable derivatives thereof in the treatment of HBV infections.


Furthermore, there is provided, in a fourth aspect of the invention, the use of β -L-5F-ddC and pharmaceutically acceptable derivatives thereof for the treatment of HIV infections.

There is also provided, in a fifth aspect of the invention, the use of β -L-5F-ddC and pharmaceutically acceptable derivatives thereof for the treatment of HBV

4


infections.

These compounds are represented by formula (I):




(I)

wherein X is hydrogen or fluoro. The compounds of formula (I) are racemic mixtures of the two enantiomers of formulae (Ia) and (Ib):



(Ia)



(Ib)

10 The (-)-enantiomer of ddC has the absolute configuration of 1'S at the carbon bearing the base and 4'R at the carbon bearing the CH₂OH moiety. It has the absolute stereochemistry of the compound of formula (Ib) and the chemical name of β-L-2',3'-dideoxycytidine or (1'S,4'R)-2',3'-dideoxycytidine (hereinafter Compound A).

The (+)-enantiomer of 5F-ddC has the absolute stereochemistry of the compound of formula (Ia) and the chemical name of β-D-5-fluoro-2',3'-dideoxycytosine (hereinafter Compound B).

20

The (-)-enantiomer of 5F-ddC has also the absolute

stereochemistry of the compound of formula (Ib) and the chemical name of β -L-5-fluoro-2',3'-dideoxycytosine (hereinafter Compound C).

Preferably compound A or C are provided substantially free of the corresponding (+)-enantiomer, that is to say no more than about 5% w/w of the (+)- enantiomer, preferably no more than about 2%, in particular less than about 1% w/w is present.

Preferably compound B is provided substantially free
10 of the corresponding (-)-enantiomer, that is to say no more than about 5% w/w of the (-)- enantiomer, preferably no more than about 2%, in particular less than about 1% w/w is present.

By "a pharmaceutically acceptable derivative" is meant any pharmaceutically acceptable salt, ester, or salt of such ester, of compound A, B or C or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) compound A, B or C or an antivirally active metabolite or residue thereof.

20 It will be appreciated by those skilled in the art that compound A, B or C may be modified to provide pharmaceutically acceptable derivatives thereof, at functional groups in both the base moiety and at the hydroxymethyl group of the oxathiolane ring. Modification at all such functional groups are included within the scope of the invention. However of particular interest are pharmaceutically acceptable derivatives obtained by

modification of the 2-hydroxymethyl group at 4'-carbon of the sugar ring.

Preferred esters of compound A, B or C include the compounds in which the hydrogen of the 2-hydroxymethyl group is replaced by an acyl function R-C(O)- in which the non-carbonyl moiety R of the ester is selected from hydrogen, straight or branched chain alkyl (e.g. methyl, ethyl, n-propyl, t-butyl, n-butyl), alkoxyalkyl (e.g. methoxymethyl), aralkyl (e.g. benzyl), aryloxyalkyl (e.g. 10 phenoxymethyl), aryl (e.g. phenyl optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy); sulphonate esters such as alkyl- or aralkylsulphonyl (e.g. methanesulphonyl); amino acid esters (e.g. L-valyl or L-isoleucyl) and mono-, di- or tri-phosphate esters.

With regard to the above described esters, unless otherwise specified, any alkyl moiety present advantageously contains 1 to 16 carbon atoms, particularly 1 to 4 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group.

20 In particular the esters may be a C₁₋₁₆ alkyl ester, an unsubstituted benzyl ester or a benzyl ester substituted by at least one halogen (bromine, chlorine, fluorine or iodine), C₁₋₆ alkyl, C₁₋₆ alkoxy, nitro or trifluoromethyl groups.

Pharmaceutically acceptable salts of the compound A, B or C include those derived from pharmaceutically acceptable inorganic and organic acids and bases.

Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toleune-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium), ammonium and NR_4^+ (where R is C_{1-4} alkyl) salts.

References hereinafter to a compound according to the invention include, the compound A, B or C and their pharmaceutically acceptable derivatives.

The compounds of the invention either themselves possess antiviral activity and/or are metabolizable to such compounds. In particular these compounds are effective in inhibiting the replication of retroviruses, including human retroviruses such as human immunodeficiency viruses (HIV's), the causative agents of AIDS.

There is thus provided as a further aspect of the invention compound A, B or C or a pharmaceutically acceptable derivative thereof for use as an active

therapeutic agent in particular as an antiviral agent, for example in the treatment of retroviral infections or infections by viruses known to possess reverse transcriptase activity (such as Hepatitis B virus).

In a further or alternative aspect there is provided a method for the treatment of a viral infection, in particular an infection caused by a retrovirus such as HIV, or by a virus possessing retroviral activity such as HBV in a mammal including man comprising administration of
10 an effective amount of compound A, B or C or a pharmaceutically acceptable derivative thereof.

There is also provided in a further or alternative aspect use of compound A, B or C or a pharmaceutically acceptable derivative thereof for the manufacture of a medicament for the treatment of a viral infection.

The compounds of the invention are also useful in the treatment of HBV or of AIDS related conditions such as AIDS-related complex (ARC), progressive generalised lymphadenopathy (PGL), AIDS-related neurological
20 conditions (such as dementia or tropical paraparesis), anti-HIV antibody positive and HIV- positive conditions, Kaposi's sarcoma, thrombocytopenia purpurea and associated opportunistic infections for example Pneumocystis carinii.

The compounds of the invention are also useful in the prevention of progression to clinical illness of individuals who are anti-HIV or HBV antibody or HIV-or HBV-antigen positive and in prophylaxis following exposure

to HIV or HBV.

The compound A, B or C or pharmaceutically acceptable derivatives thereof may also be used for the prevention of viral contamination of physiological fluids such as blood or semen in vitro.

It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established infections or symptoms.

10 It will be further appreciated that the amount of a compound of the invention required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general however a suitable dose will be in the range of from about 0.1 to about 750mg/kg of bodyweight per day preferably in the range of 0.5 to 60mg/kg/day, most preferably in the
20 range of 1 to 20mg/kg/day.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

The compound is conveniently administered in unit dosage form; for example containing 10 to 1500mg, conveniently 20 to 1000mg, most conveniently 50 to 700mg

of active ingredient per unit dosage form.

Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 1 to about 75 μ M, preferably about 2 to 50 μ M, most preferably about 3 to about 30 μ M. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1 to about 100mg of the active ingredient.

10 Desirable blood levels may be maintained by a continuous infusion to provide about 0.01 to about 5.0 mg/kg/hour or by intermittent infusions containing about 0.4 to about 15 mg/kg of the active ingredient.

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical it is preferable to present the active ingredient as a pharmaceutical formulation.

The invention thus further provided a pharmaceutical formulation comprising compound A, B or C or a
20 pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers therefor and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

Pharmaceutical formulations include those suitable

for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, sub-cutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation. The formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active compound with liquid
10 carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

Pharmaceutical formulations suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution, a suspension or as an emulsion. The active ingredient may also be presented as a bolus, electuary or paste. Tablets and capsules for oral
20 administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid

preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), or preservatives.

The compounds according to the invention may also be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The
10 compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

For topical administration to the epidermis the compounds according to the invention may be formulated as
20 ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.

Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most
10 preferably presented as unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art, and the suppositories may be conveniently formed by admixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in moulds.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be
20 appropriate.

For intra-nasal administration the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops.

Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilising agents or suspending agents. Liquid sprays are conveniently delivered from pressurised packs.

For administration by inhalation the compounds according to the invention are conveniently delivered from an insufflator, nebuliser or a pressurised pack or other convenient means of delivering an aerosol spray. Pressurised packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to
10 deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges or e.g. gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.

20 When desired the above described formulations adapted to give sustained release of the active ingredient may be employed.

The pharmaceutical compositions according to the invention may also contain other active ingredients such as antimicrobial agents, or preservatives.

The compounds of the invention may also be used in combination with other therapeutic agents for example

other antiinfective agents. In particular the compounds of the invention may be employed together with known antiviral agents.

The invention thus provides, in a further aspect, a combination comprising the compound A, B or C or a physiologically acceptable derivative thereof together with another therapeutically active agent, in particular an antiviral agent.

The combinations referred to above may conveniently
10 be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefor comprise a further aspect of the invention.

Suitable therapeutic agents for use in such combinations include acyclic nucleosides such as acyclovir or ganciclovir, interferons such as α , β or γ -interferon, renal excretion inhibitors such as probenecid, nucleoside transport inhibitors such as dipyrnidamole, 1,3-oxathiolane
20 nucleoside analogues, such as 3TC, 2',3'-dideoxynucleosides such as AZT, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-dideoxythymidine, 2',3'-dideoxy-2'3'-didehydrothymidine and 2',3'-dideoxy-2',3'-didehydrocytidine, FIAU, immunomodulators such as interleukin II (IL2) and granulocyte macrophage colony stimulating factor (GM-CSF), erythropoietin, amipligen, thymomodulin, thymopentin, foscarnet, ribavirin, and

inhibitors of HIV binding to CD4 receptors e.g. soluble CD4, CD4 fragments, CD4 hybrid molecules, glycosylation inhibitors such as 2-deoxy-D-glucose, castanospermine and 1-deoxynojirimycin.

The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When the compound A, B or C or a pharmaceutically acceptable derivative thereof is used in combination with
10 a second therapeutic agent active against the same virus the dose of each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

The compound A, B or C and their pharmaceutically acceptable derivatives may be prepared by any method known in the art for the preparation of compounds of analogous structure, for example as described in international publication No. WO 92/20969 which is herein incorporated
20 by reference.

It will be appreciated by those skilled in the art that for certain of the methods the desired stereochemistry of the compound A, B or C may be obtained either by commencing with an optically pure starting material or by resolving the racemic mixture at any convenient stage in the synthesis. In the case of all the processes the optically pure desired product may be

obtained by resolution of the end product of each reaction.

Example 1 Antiviral activity & Cytotoxicity

A) MT-4 Formazan Assay

Antiviral activity was determined in MT-4 cells by inhibition of formazan conversion (Baba & al., (1987) 10 Biochem. Biophys. Res. Commun. 142, 128-134; Mossman (1983) J. Immun. Meth.; 65, 55-57).

B) Inhibition of Syncytium Formation Assay

C8166 cells were infected with HIV-1 (strain RF) at a moi of 1×10^{-3} infectious units/cell and adsorbed at room temperature for 60 minutes. After adsorption, the cells were washed three times in growth medium. Aliquots of 10^5 cells were added to each well of 24-well plates containing 20 serial dilutions of test compounds at final concentrations of 50 μ g/ml to 0.05 μ g/ml in RPMI® 1640 growth medium. Untreated infected cells and untreated uninfected cells were also included as controls. The plates were incubated at 37°C/5% CO₂ for 3-4 days in humidified containers. The cells were examined daily for evidence of HIV-1 induced syncytium formation. The syncytia were quantified by reference to the untreated infected controls, and the dose

of compound required to reduce the cytopathic effect by 50% (ID₅₀) was calculated.

C) Cytotoxicity

The cytotoxicities of the compounds were determined in five CD4 cell lines: H9, JM, CEM, C8166 and U937.

Compounds for test were serially diluted from 100 µg/ml to 0.3 µg/ml (final concentrations) in 96 well microtitre plates. 3.6×10^4 cells were inoculated into 10 each well of the plates including drug-free controls. After incubation at 37°C for 5 days, the viable cell count was determined by removing a sample of cell suspension and counting trypan blue excluding cells in a haemocytometer.

Results are shown in Table 1.

D) Inhibition of Human Hepatitis B virus.

The method used for this test is described in detail in 20 Korba et al., Antiviral Research 15, 217-228 (1992) which is shortly described as follows:

Hep G2 cells transfected with human hepatitis B virus genomic DNA (2.2.15 cells) were grown and maintained in RPMI-1640 culture medium containing 5 foetal bovine serum, 2mM glutamine and 50µg/ml gentamicin sulphate, and checked routinely for G418 resistance. Cultures of 2.2.15 cells were grown to confluence in 24 well tissue culture

plates and maintained for 2 to 3 days in that condition prior to drug treatment.

Drugs were dissolved in sterile water or sterile 50% DMSO in water at concentrations 100-fold higher than the higher test concentration. These solutions were diluted as needed in culture medium.

The culture medium on the confluent cells was changed 24 hours prior to exposure to test compounds. During the 10 day treatment, the culture medium was changed daily.

10 After 10 days of the treatment, the culture medium was collected and frozen at -70°C for HBV DNA analysis.

To analyse extracellular HBV DNA, 0.2ml samples of culture medium were incubated for 20 minutes at 25°C in 1M NaOH/10X SSC (1X SSC is 0.15M NaCl/ 0.015M Sodium Citrate, pH 7.2) and then applied to nitrocellulose membranes presoaked in 20X SSC. Filters were then rinsed in 2X SSC and baked at 80°C for 1 hour under vacuum.

A purified 3.2 kb EcoR1 HBV DNA fragment was labelled with [³²P]dCTP by nick translation and used as a probe to 20 detect HBV DNA on the dot-blot by DNA hybridisation. After washing, the hybridised blot was dried and ³²p was quantified using an Ambis beta scanner.

Results are shown in Table 2.

TABLE I

50% Antiviral Activity against HIV in $\mu\text{g/ml}$ (μM)

| Assay | Formazan | | Cytotoxicity | Syncytium | | Formation Cytotoxicity |
|--------------------------------------|--------------------|--|----------------|-------------------|--|------------------------|
| | Antiviral | | | Antiviral | | |
| AZT (natural) | 0.0022 (0.0092) | | >1 | 0.002 (0.0084) | | >0.5 |
| A) β -L-ddC (-) (unnatural) | 0.022 (0.1) | | >100 (>474) | 0.014 (0.067) | | >5 (>24) |
| B) β -D-5F-ddC (+) (natural) | 0.145 (0.63) | | 10 (44) | 0.0056 (0.02) | | >0.5 (>2.2) |
| C) β -L-5F-ddC (-) (unnatural) | 0.05 (0.22) | | 1 (4.4) | 0.011 (0.05) | | >0.5 (>2.2) |


TABLE 2

50% Antiviral Activity against HBV in $\mu\text{g/ml}$

| Assay | Hepatitis B Virus | |
|--------------------------------------|-------------------|--------------|
| | Antiviral | Cytotoxicity |
| AZT | | |
| A) β -L-ddC (-) (unnatural) | 0.44 | >10 |
| B) β -D-5F-ddC (+) (natural) | <10 | >10 |
| C) β -L-5F-ddC (-) (unnatural) | <10 | >10 |

What is claimed is:


1. The use of a β -L enantiomer of formula (Ia) and pharmaceutically acceptable derivatives thereof:



wherein X is hydrogen or fluorine,
in the treatment of viral infections.


2. The use according to claim 1 wherein said enantiomer contains no more than about 5% w/w of the corresponding β -D-enantiomer.
3. The use according to claim 2 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -D-enantiomer.
4. The use according to claim 3 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -D-enantiomer.
5. The use of a β -L enantiomer according to claim 1, wherein said viral infection is an HIV infection.
6. The use of a β -L enantiomer according to claim 1, wherein said viral infection is a hepatitis B infection.
7. The use of an enantiomer according to claim 1, wherein said enantiomer is β -L-5-fluoro-2', 3' - dide xycytosine.

8. The use of an enantiomer according to claim 1, wherein said enantiomer is β -L- 2', 3' - dideoxycytidine.
9. The use of an enantiomer of formula (Ia) and pharmaceutically acceptable derivatives thereof:



wherein X is hydrogen or fluorine,
for the manufacture of a medicament for the treatment
of viral infections.

10. The use of an enantiomer according to claim 9 wherein said viral infection is an HIV infection.
11. The use of an enantiomer according to claim 9 wherein said viral infection is a hepatitis B infection.
12. The use of a β -D-enantiomer of formula (Ib) and pharmaceutically acceptable derivatives thereof:




in the treatment of hepatitis B viral infections.

13. The use according to claim 12 wherein said enantiomer

contains no more than about 5% w/w of the corresponding β -L-enantiomer.

14. The use according to claim 13 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -L-enantiomer.
15. The use according to claim 14 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -L-enantiomer.
16. The use of an enantiomer of formula (Ib) and pharmaceutically acceptable derivatives thereof:



(Ib)

for the manufacture of a medicament for the treatment of hepatitis B viral infections.

17. The use according to claim 9, 10, 11, or 16, wherein said medicament is administered orally, parentally, rectally, nasally, vaginally, or topically.
18. The use according to claim 17, wherein said medicament is administered at a dose of about 0.1 to at least 750 mg/kg of bodyweight per day.
19. The use according to claim 18 wherein said medicament is administered at a dose of about 0.5 to at least 60 mg/kg of bodyweight per day.
20. The use according to claim 19, wherein said medicament


25

is administered at a dose of about 1.0 to at least 20 mg/kg of bodyweight per day.

21. The use according to claim 17, wherein said enantiomer is present in dosage unit form in the medicament.
22. The use according to claim 21 wherein said enantiomer is present in dosage unit form in the medicament at about 10 to 1500 mg.
23. The use according to claim 22 wherein said enantiomer is present in dosage unit form in the medicament at about 20 to 1000 mg.
24. The use according to claim 23 wherein said enantiomer is present in dosage unit form in the medicament at about 50 to 700 mg.
25. The use according to any one of claims 9, 10, 11, 16, 18, 19, 20, 21, 22, 23 or 24 wherein said medicament is administered in admixture with a pharmaceutically acceptable carrier.
26. The use according to claim 25 wherein said medicament is administered with another therapeutically active agent.
27. The use according to claim 26 wherein said therapeutically active agent is an antiviral agent.
28. The use according to claim 17 wherein said medicament is administered in admixture with a pharmaceutically acceptable carrier.
29. The use according to claim 28 wherein said medicament is administered with a therapeutically active agent.
30. The use according to claim 29 wherein said

therapeutically active agent is an antiviral agent.


31. A method for the treatment of viral infections comprising the step of administering a pharmaceutically effective amount of a β -L enantiomer of formula (Ia) or pharmaceutically acceptable derivatives thereof:



wherein X is hydrogen or fluorine.

32. The method according to claim 31 wherein said enantiomer contains no more than about 5% w/w of the corresponding β -D-enantiomer.
33. The method according to claim 32 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -D-enantiomer.
34. The method according to claim 33 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -D-enantiomer.
35. The method according to claim 31 wherein said viral infection is an HIV infection.
36. The method according to claim 31, wherein said viral infection is a hepatitis B infection.
37. The method according to claim 31, wherein said enantiomer is β -L-5-fluoro-2', 3' - dideoxycytosine.

38. The method according to claim 31, wherein said enantiomer is β -L-2',3'- dideoxycytidine.
39. A method for the treatment of hepatitis B viral infections comprising the step of administering a pharmaceutically effective amount of a β -D enantiomer of formula (Ib):



or pharmaceutically acceptable derivatives thereof.


40. The method according to claim 39 wherein said enantiomer contains no more than about 5% w/w of the corresponding β -L-enantiomer.
41. The method according to claim 40 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -L-enantiomer.
42. The method according to claim 41 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -L-enantiomer.
43. The method according to claim 31 or 39, wherein said administration is carried out at a dose of about 0.1 to at least 750 mg/kg of bodyweight per day.
44. The method according to claim 43 wherein said administration is carried out at a dose of about 0.5 to at least 60 mg/kg of bodyweight per day.

45. The method according to claim 44, wherein said administration is carried out at a dose of about 1.0 to at least 20 mg/kg of bodyweight per day.
46. The method according to claim 31 or 39, wherein said enantiomer is administered in dosage unit form.
47. The method according to claim 46 wherein said enantiomer is administered in dosage unit form in the amount of about 10 to 1500 mg.
48. The method according to claim 47 wherein said enantiomer is administered in dosage unit form in the amount of about 20 to 1000 mg.
49. The method according to claim 48 wherein said enantiomer is administered in dosage unit form in the amount of about 50 to 700 mg.
50. The method according to any one of claims 43, 44, 45, 46, 47, 48 or 49 wherein said administration is carried out in admixture with a pharmaceutically acceptable carrier.
51. The method according to claim 50 wherein said administration is carried out with another therapeutically active agent.
52. The method according to claim 51 wherein said therapeutically active agent is an antiviral agent.

AMENDED CLAIMS

[received by the International Bureau on 30 May 1994 (30.05.94);
original claims 1-52 replaced by amended claims 1-62
(10 pages)]


1. The use of a β -L enantiomer of formula (Ia) and pharmaceutically acceptable derivatives thereof:



(Ia)

in the treatment of viral infections.

2. The use of a β -L enantiomer according to claim 1, wherein said viral infection is an HIV infection.
3. The use of a β -L enantiomer according to claim 1, wherein said viral infection is a hepatitis B infection.
4. The use of a β -D-enantiomer of formula (Ib) and pharmaceutically acceptable derivatives thereof:




(Ib)

in the treatment of hepatitis B viral infections.


5. The use according to claim 4 wherein said enantiomer contains more than about 5% w/w of the corresponding β -L-enantiomer.

6. The use according to claim 5 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -L-enantiomer.
7. The use according to claim 6 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -L-enantiomer.
8. The use of a β -L enantiomer of formula (Ic) and pharmaceutically acceptable derivatives thereof:



in the treatment of hepatitis B viral infections.


9. The use according to claim 1 or 8 wherein said enantiomer contains no more than about 5% w/w of the corresponding β -D-enantiomer.
10. The use according to claim 1 or 8 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -D-enantiomer.
11. The use according to claim 1 or 8 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -D-enantiomer.
12. The use of an enantiomer of formula (Ia) and pharmaceutically acceptable derivatives thereof:



(Ia)

for the manufacture of a medicament for the treatment of viral infections.

13. The use of an enantiomer according to claim 12 wherein said viral infection is an HIV infection.
14. The use of an enantiomer according to claim 12 wherein said viral infection is a hepatitis B infection.
15. The use of an enantiomer of formula (Ib) and pharmaceutically acceptable derivatives thereof:




(Ib)

for the manufacture of a medicament for the treatment of hepatitis B viral infections.

16. The use according to claim 15 wherein said medicament contains no more than about 5% w/w of the corresponding β -L-enantiomer.


17. The use according to claim 16 wherein said medicament contains no more than about 2% w/w of the corresponding β -L-enantiomer.
18. The use according to claim 17 wherein said medicament contains no more than about 1% w/w of the corresponding β -L-enantiomer.
19. The use of an enantiomer of formula (Ic) and pharmaceutically acceptable derivatives thereof:



- for the manufacture of a medicament for the treatment of hepatitis B viral infections.
20. The use according to claim 12 or 19 wherein said medicament contains no more than about 5% w/w of the corresponding β -D-enantiomer.
21. The use according to claim 20 wherein said medicament contains no more than about 2% w/w of the corresponding β -D-enantiomer.
22. The use according to claim 21 wherein said medicament contains no more than about 1% w/w of the corresponding β -D-enantiomer.

23. The use according to claim 12, 13, 14, 15, or 19, wherein said medicament is administered orally, parentally, rectally, nasally, vaginally, or topically.
24. The use according to claim 23, wherein said medicament is administered at a dose of about 0.1 to at least 750 mg/kg of body weight per day.
25. The use according to claim 24 wherein said medicament is administered at a dose of about 0.5 to at least 60 mg/kg of body weight per day.
26. The use according to claim 25, wherein said medicament is administered at a dose of about 1.0 to at least 20 mg/kg of body weight per day.
27. The use according to claim 23, wherein said enantiomer is present in dosage unit form in the medicament.
28. The use according to claim 27 wherein said enantiomer is present in dosage unit form in the medicament at about 10 to 1500 mg.
29. The use according to claim 28 wherein said enantiomer is present in dosage unit form in the medicament at about 20 to 1000 mg.
30. The use according to claim 29 wherein said enantiomer is present in dosage unit form in the medicament at about 50 to 700 mg.
31. The use according to any one of claims 12, 13, 14, 15, 19, 24, 25, 26, 27, 28, 29 or 30 wherein said medicament is administered in admixture with a pharmaceutically acceptable carrier.


32. The use according to claim 23 wherein said medicament is administered in admixture with a pharmaceutically acceptable carrier.
33. The use according to claim 31 wherein said medicament is administered with another therapeutically active agent.
34. The use according to claim 32 wherein said medicament is administered with a therapeutically active agent.
35. The use according to claim 33 or 34 wherein said therapeutically active agent is an antiviral agent.
36. A method for the treatment of viral infections comprising the step of administering a pharmaceutically effective amount of a β -L enantiomer of formula (Ia):



or pharmaceutically acceptable derivatives thereof.


37. The method according to claim 36 wherein said viral infection is an HIV infection.
38. The method according to claim 36, wherein said viral infection is a hepatitis B infection.
39. A method for the treatment of hepatitis B viral infections comprising the step of administering a

pharmaceutically effective amount of a β -D enantiomer of formula (Ib):



or pharmaceutically acceptable derivatives thereof.

40. The method according to claim 39 wherein said enantiomer contains no more than about 5% w/w of the corresponding β -L-enantiomer.
41. The method according to claim 40 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -L-enantiomer.
42. The method according to claim 41 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -L-enantiomer.
43. A method for the treatment of hepatitis B viral infections comprising the step of administering a pharmaceutically effective amount of a β -L enantiomer of formula (Ic):



36

(Ic)

or pharmaceutically acceptable derivatives thereof.

44. The method according to claim 36 or 43 wherein said enantiomer contains no more than about 5% w/w of the corresponding β -D-enantiomer.
45. The method according to claim 44 wherein said enantiomer contains no more than about 2% w/w of the corresponding β -D-enantiomer.
46. The method according to claim 45 wherein said enantiomer contains no more than about 1% w/w of the corresponding β -D-enantiomer.
47. The method according to claim 36, 39, or 43, wherein said administration is carried out at a dose of about 0.1 to at least 750 mg/kg of body weight per day.
48. The method according to claim 47 wherein said administration is carried out at a dose of about 0.5 to at least 60 mg/kg of body weight per day.
49. The method according to claim 48, wherein said administration is carried out at a dose of about 1.0 to at least 20 mg/kg of body weight per day.
50. The method according to claim 36, 39, or 43, wherein said enantiomer is administered in dosage unit form.
51. The method according to claim 50 wherein said enantiomer is administered in dosage unit form in the amount of about 10 to 1500 mg.

52. The method according to claim 51 where in said enantiomer is administered in dosage unit form in the amount of about 20 to 1000 mg.
53. The method according to claim 52 wherein said enantiomer is administered in dosage unit form in the amount of about 50 to 700 mg.
54. The method according to claim 47 wherein said administration is carried out in admixture with a pharmaceutically acceptable carrier.
55. The method according to any one of claims 48, 49, 51, 52 or 53 wherein said administration is carried out in admixture with a pharmaceutically acceptable carrier.
56. The method according to claim 50, wherein said administration is carried out in admixture with a pharmaceutically acceptable carrier.
57. The method according to claim 54 or 56 wherein said administration is carried out with another therapeutically active agent.
58. The method according to claim 55 wherein said administration is carried out with another therapeutically active agent.
59. The method according to claim 57 wherein said therapeutically active agent is an antiviral agent.
60. The method according to claim 58 wherein said therapeutically active agent is an antiviral agent.
61. The method according to claim 59 and 60 wherein said antiviral agent is AZT.

38

62. The method according to claim 59 or 60 wherein said antiviral agent is 3TC™.

INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/CA 93/00563

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|--|
| X | EP,A,0 285 884 (BRISTOL-MYERS COMPANY) 12 October 1988 see the whole document especially page 17, table | 1-5, 8-10, 17-25, 28, 31-35, 38,43-50 |
| X | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 1, no. 1, 1991 pages 65 - 68 MANSURI, M.M. ET AL 'PREPARATION OF THE GEOMETRIC ISOMERS OF DDC, DDA, D4C AND D4T AS POTENTIAL HIV AGENTS' cited in the application see the whole document especially page 66, line 14-20 | 1-5, 8-10, 17-25, 28, 31-35, 38,43-50 |
| -/- | | |

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

21 March 1994

Date of making of the international search report

30.03.94

Name and mailing address of the ISA

European Patent Office, P.O. 2818 Patentamt 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 631 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Mair, J

INTERNATIONAL SEARCH REPORT.

Int. Patent Application No

PCT/CA 93/00563

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|--|
| X | EP,A,0 352 248 (MEDIVIR AKTIEBOLAG) 24 January 1990 see the whole document | 1-6, 8-11, 17-25, 28, 31-36, 38,43-50 |
| A | THE JOURNAL OF MEDICINAL CHEMISTRY vol. 30, no. 5, 1987 pages 862 - 866 KIM, C-H. ET AL 'POTENTIAL ANTI-AIDS DRUGS. 2',3'-DIDEOXYCYTIDINE ANALOGUES' cited in the application see the whole document | 1-52 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA93/00563

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ **Claims Nos.:**
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 31-52 are directed towards a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compounds.
2. ☐ **Claims Nos.:**
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ **Claims Nos.:**
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6A(s).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. National Application No

PCT/CA 93/00563

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP-A-0285884 | 12-10-88 | AU-B- 610865 | 30-05-91 |
| | | AU-A- 1327788 | 29-09-88 |
| | | AU-A- 7134991 | 23-05-91 |
| | | JP-A- 64000098 | 05-01-89 |
| EP-A-0352248 | 24-01-90 | AU-A- 3978689 | 19-02-90 |
| | | WO-A- 9001036 | 08-02-90 |

INTERNATIONAL SEARCH REPORT

In national application No.

PCT/CA 93/00553

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|---|-----------------------|
| Y | STN International, File CA, Chemical Abstracts, volume 81, no. 25, 23 December 1974 (Columbus Ohio, US), B. Fouque et al: "Inhibition of Ehrlich ascites cell thymidine kinase by a new class of nucleoside derivatives", abstract no. 165382m, & Chemotherapy (Basel), 20(4), 221-6 1974 -- | 1-56 |
| A | STN International, File CA, Chemical Abstracts, volume 115, no. 11, 16 September 1991 (Columbus, Ohio, US), Lien Eric J. et al: "Physical factors contributing to the partition coefficient and retention time of 2',3'-dideoxynucleoside analogs", J. Pharm. Sci., 80(6), 517-21 -- | 1-56 |
| A | STN International, File CA, Chemical Abstracts, volume 114, no. 21, 27 May 1991 (Columbus, Ohio, US), Cretton Erika M. et al: "Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells", Mol. Pharmacol., 39(2), 258-66 -- | 1-56 |
| A | STN International, File CA, Chemical Abstracts, volume 110, no. 1, 2 January 1989 (Columbus, Ohio, US), Chu Chung K. et al: "Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells", Biochem. Pharmacol., 37(19), 3543-8 -- | 1-56 |
| A | STN International, File CA, Chemical Abstracts, volume 110, no. 13, 27 March 1989 (Columbus, Ohio, US), Chu Chung K. et al: "Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells", J. Med. Chem., 32(3), 612-17 -- ----- | 1-56 |